Graves Orbitopathy Market Size (7MM) Reached ~USD 2060 Million in 2024

The Graves Orbitopathy Market in the 7MM was valued at ~USD 2060 million in 2024, over the forecast period from 2025 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Graves Orbitopathy Market Landscape.

By analyzing historical data, current Graves Orbitopathy Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The Graves Orbitopathy Market is increasingly guided by biomarker-driven strategies. Graves’ Orbitopathy (GO), also known as thyroid eye disease (TED), is an autoimmune condition that affects the tissues around the eyes, typically associated with Graves’ disease, an autoimmune thyroid disorder. In GO, the body’s immune system mistakenly attacks the muscles and connective tissues behind the eyes, leading to inflammation and tissue remodeling.

DelveInsight’s report, “Graves Orbitopathy Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Graves Orbitopathy Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Graves Orbitopathy Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Graves Orbitopathy Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Graves Orbitopathy Market Forecast

Some of the key facts of the Graves Orbitopathy Market Report

• The leading Graves Orbitopathy Companies, such as Amgen (Horizon Therapeutics), Viridian Therapeutics, Argenx, Tourmaline Bio and others.
• Promising Graves Orbitopathy Therapies such as Teprotumumab, MHB018A, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, AMG 732, IBI311, Teprotumumab, lonigutamab and others.
• The Graves Orbitopathy Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching multiple-stage Graves Orbitopathy Pipeline products will significantly revolutionize the Graves Orbitopathy Market Dynamics.

Graves Orbitopathy Overview

Graves’ Orbitopathy (GO) is an autoimmune condition affecting the eyes, most commonly seen in patients with Graves’ disease. In GO, immune-mediated inflammation targets the muscles and connective tissues within the orbit, causing tissue swelling and fat expansion. This can lead to symptoms such as bulging eyes, eyelid retraction, double vision, and eye discomfort, and in severe cases, vision impairment due to optic nerve compression. The disorder often follows a course of an active inflammatory phase and a subsequent chronic phase, with treatment strategies ranging from medications that reduce inflammation to surgical procedures that correct structural changes.

Get a Free sample for the Graves Orbitopathy Market Report @ https://www.delveinsight.com/report-store/graves-orbitopathy-market

Key Trends in Graves Orbitopathy Therapeutics Market

1. Emergence of Targeted Biologic Therapies

The introduction of monoclonal antibodies and other targeted biologics, such as Teprotumumab, has transformed the treatment landscape by directly addressing the underlying autoimmune mechanisms, offering improved efficacy compared to conventional corticosteroid therapy.

2. Shift Toward Non-Surgical Interventions

There is increasing adoption of medical management over surgical options for moderate-to-severe cases, with clinicians focusing on early pharmacological intervention to prevent disease progression and reduce the need for orbital decompression surgeries.

3. Personalized and Precision Medicine Approaches

Therapeutic strategies are increasingly being tailored to individual patient profiles, taking into account disease severity, activity, and biomarker status, which enhances treatment response and reduces adverse effects.

4. Expansion of Clinical Trials and Pipeline Candidates

Several novel molecules and repurposed drugs are advancing through preclinical and clinical stages, targeting pathways such as IGF-1 receptor, TSH receptor, and inflammatory cytokines, signaling a robust pipeline and growing R&D investment.

5. Growing Awareness and Early Diagnosis Initiatives

Enhanced physician awareness and improved diagnostic protocols, including orbital imaging and antibody profiling, are driving early detection, which is critical for the success of new therapeutic interventions.

6. Combination Therapy Approaches

Combining immunomodulatory drugs with biologics or low-dose corticosteroids is gaining attention, aiming to maximize efficacy while minimizing side effects and improving long-term patient outcomes.

7. Market Expansion in Emerging Economies

Increasing healthcare infrastructure, rising prevalence of thyroid disorders, and improved access to specialty care in emerging markets are contributing to the global growth of Graves Orbitopathy therapeutics.

Graves Orbitopathy Epidemiology

As the market is derived using a patient-based model, the Graves orbitopathy epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of Graves' disease, total diagnosed prevalent cases of Graves' disease, total diagnosed prevalent cases of Graves’ orbitopathy, gender-specific diagnosed prevalent cases of Graves’ orbitopathy, chronicity-specific diagnosed prevalent cases of Graves’ orbitopathy, and severity-specific diagnosed prevalent cases of Graves’ orbitopathy in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Graves Orbitopathy Epidemiology Segmentation:-

The Graves Orbitopathy Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Prevalent Cases of Graves' Disease
• Total Diagnosed Prevalent Cases of Graves' Disease
• Total Diagnosed Prevalent Cases of Graves’ Orbitopathy
• Gender-specific Diagnosed Prevalent Cases of Graves’ Orbitopathy
• Chronicity-specific Diagnosed Prevalent Cases of Graves’ Orbitopathy
• Severity-specific Diagnosed Prevalent Cases of Graves’ Orbitopathy

Download the report to understand which factors are driving Graves Orbitopathy Epidemiology trends @ Graves Orbitopathy Epidemiology Forecast

Recent Development in the Graves Orbitopathy Treatment Landscape

• In December 2025, Amgen initiated a study to evaluate the safety and tolerability of AMG 732 following single subcutaneous (SC) doses. The primary objective of Part B of the study is to assess the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Graves Orbitopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential Graves Orbitopathy drugs recently launched in the Graves Orbitopathy market or expected to get launched during the study period. The analysis covers Graves Orbitopathy Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Graves Orbitopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Graves Orbitopathy Companies and Therapies

·        Amgen: Teprotumumab

·        Minghui Pharmaceutical (Hangzhou) Ltd: MHB018A

·        Immunovant Sciences GmbH: RVT-1401

·        Viridian Therapeutics Inc: VRDN-003

·        Immunovant Sciences GmbH: Batoclimab

To know more about Graves Orbitopathy Companies working in the treatment market, visit @ Graves Orbitopathy Clinical Trials and Therapeutic Assessment

Graves Orbitopathy Market Drivers

1. Rising Prevalence of Thyroid Disorders

The increasing incidence of autoimmune thyroid diseases, particularly Graves’ disease, is a primary driver for the Graves Orbitopathy (GO) market. As more patients develop hyperthyroidism, the likelihood of associated ocular complications rises, driving demand for effective Graves Orbitopathy therapies.

2. Growing Awareness and Early Diagnosis

Enhanced awareness among patients and healthcare professionals about the signs and symptoms of Graves Orbitopathy —such as eye bulging, double vision, and eyelid retraction—is leading to earlier diagnosis and intervention, which fuels market growth.

3. Advances in Targeted Therapeutics

Development of novel biologics, immunomodulators, and targeted therapies specifically addressing the underlying immune-mediated mechanisms of Graves Orbitopathy is expanding treatment options and improving patient outcomes, thereby propelling market demand.

4. Increasing Adoption of Minimally Invasive Procedures

Surgical interventions and radiotherapy techniques for severe or refractory cases are becoming more precise and less invasive, offering safer and more effective management options that support market expansion.

5. Rising Patient Population with Severe and Moderate Disease

A significant proportion of patients with moderate-to-severe Graves Orbitopathy require specialized treatment to manage inflammation, proptosis, and diplopia. The growing pool of patients needing these interventions drives demand for both pharmacological and surgical solutions.

Graves Orbitopathy Market Barriers

1. Limited Approved Treatment Options

The number of therapies specifically approved for Graves Orbitopathy (GO) is limited, with most treatments focusing on symptom management rather than addressing the underlying disease. This constrains therapeutic adoption and slows market growth.

2. Complex Disease Pathophysiology

Graves Orbitopathy involves autoimmune-mediated inflammation of orbital tissues, leading to eye bulging, double vision, and tissue remodeling. The complex and multifactorial nature of the disease makes drug development challenging and contributes to high research and development costs.

3. Diagnostic Challenges and Delayed Detection

Early-stage Graves Orbitopathy can be subtle, with symptoms often mistaken for general thyroid dysfunction or fatigue. Delayed diagnosis hampers timely intervention, limiting the effectiveness of available therapies and reducing market penetration.

4. Variability in Disease Severity

Patients exhibit a wide spectrum of disease severity, from mild eye irritation to sight-threatening complications. This heterogeneity complicates clinical trial design, endpoint selection, and regulatory approval processes.

5. High Treatment Costs

Advanced therapies, especially biologics and monoclonal antibodies, can be expensive, limiting access in cost-sensitive regions and restricting widespread adoption in both developed and emerging markets.

Scope of the Graves Orbitopathy Market Report

·        Coverage- 7MM

·        Study Period-2020-2034

·        Graves Orbitopathy Companies- Amgen (Horizon Therapeutics), Viridian Therapeutics, Argenx, Tourmaline Bio and others.

·        Graves Orbitopathy Therapies- Teprotumumab, MHB018A, RVT-1401, VRDN-003, Veligrotug (VRDN-001), Batoclimab, AMG 732, IBI311, Teprotumumab, lonigutamab

·        Graves Orbitopathy Therapeutic Assessment: Graves Orbitopathy current marketed and Graves Orbitopathy emerging therapies

·        Graves Orbitopathy Market Dynamics: Graves Orbitopathy market drivers and Graves Orbitopathy market barriers

·        Graves Orbitopathy Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

·        Graves Orbitopathy Unmet Needs, KOL’s views, Analyst’s views, Graves Orbitopathy Market Access and Reimbursement

Discover more about therapies set to grab major Graves Orbitopathy Market Share @ Graves Orbitopathy Treatment Market

Table of Contents

1. Key Insights

2. Graves Orbitopathy Market Report Introduction

3. Graves Orbitopathy Market Overview at a Glance

4. Graves Orbitopathy Executive Summary

5. Key Events

6. Graves Orbitopathy Market Disease Background and Overview

7. Graves Orbitopathy Methodology

8. E Graves Orbitopathy pidemiology and Patient Population

9. Graves Orbitopathy Patient Journey

10. Graves Orbitopathy Marketed Drugs

11. Graves Orbitopathy Emerging Drugs

12. Graves Orbitopathy – 7MM Market Analysis

13. Graves Orbitopathy KOL Views

14. Graves Orbitopathy Unmet Needs

15. Graves Orbitopathy SWOT Analysis

16. Graves Orbitopathy Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.